id: NEW:colchicine_treatment_to_NEW:covid_19_severity_reduction
name: Colchicine Treatment → COVID-19 Severity Reduction
from_node:
  node_id: NEW:colchicine_treatment
  node_name: Colchicine Treatment
to_node:
  node_id: NEW:covid_19_severity_reduction
  node_name: COVID-19 Severity Reduction
direction: negative
category: biological
mechanism_pathway:
- 'Step 1: Colchicine is administered to COVID-19 patients'
- 'Step 2: Drug inhibits microtubule polymerization and reduces inflammatory cytokine release'
- 'Step 3: Attenuation of hyperinflammatory response prevents cytokine storm'
- 'Step 4: Reduced progression from mild/moderate to severe COVID-19'
evidence:
  quality_rating: A
  n_studies: 8
  primary_citation: 'T. Hariyanto et al. 2021. "Colchicine treatment can improve outcomes of coronavirus
    disease 2019 (COVID‐19): A systematic review and meta‐analysis." https://doi.org/10.1111/1440-1681.13488'
  supporting_citations:
  - Additional citations require full-text access - subgroup analysis within meta-analysis of 8 studies
  doi: 10.1111/1440-1681.13488
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Subgroup analysis demonstrates colchicine treatment reduces progression to severe COVID-19
  (OR 0.44, 95% CI 0.31-0.63, p<0.00001, I²=0%)
quantitative_effects:
  effect_size:
    value: 0.44
    type: odds_ratio
    ci_lower: 0.31
    ci_upper: 0.63
  p_value: 1.0e-05
  sample_size: 5778
  heterogeneity_i_squared: 0.0
structural_competency:
  equity_implications: The ability to receive timely anti-inflammatory treatment depends on healthcare
    system capacity, treatment protocol adoption, and medication supply chains. Structural barriers to
    healthcare access may create inequitable distribution of treatment benefits.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.873179'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
